Results 71 to 80 of about 217,476 (395)

Inhibition of HIF-1 alpha by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma [PDF]

, 2015
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are ...
Acland, Assenat, Bazhin, Carbone, Chaput, Chen, Chouaib, Danenberg, David, Dyson, El-Deiry, Gallick, Gelovani, Ghansah, Giese, Gil, Gress, Gribben, Hao, Hao, Hao, Henson, Jemal, Kiessling, Kroemer, Kroemer, Kroemer, Levi, Luo, Mi, Moses, Plate, Powis, Powis, Powis, Ravichandran, Ricci, Rodeck, Sarker, Schuler, Semenza, Singh, Spisek, Tani, Vandenabeele, Wang, Wang, Zitvogel, Zitvogel, Zitvogel   +49 more
core   +1 more source

An Immunological Glance on Pancreatic Ductal Adenocarcinoma [PDF]

International Journal of Molecular Sciences, 2020
Pancreatic ductal adenocarcinoma (PDAC) has still a dismal prognosis. Different factors such as mutational landscape, intra- and intertumoral heterogeneity, stroma, and immune cells impact carcinogenesis of PDAC associated with an immunosuppressive microenvironment. Different cell types with partly opposing roles contribute to this milieu.
Michael Karl Melzer, Frank Arnold, Katja Stifter, Friedemann Zengerling, Ninel Azoitei, Thomas Seufferlein, Christian Bolenz, Alexander Kleger   +7 more
openaire   +2 more sources

[Pancreatic ductal adenocarcinoma]. [PDF]

Der Internist, 2019
Pancreatic ductal adenocarcinoma represents the most common malignant tumor of the pancreas. Despite substantial research efforts and gradual diagnostic and therapeutic improvements, its prognosis remains dismal. In accordance with the current German, European, and US guidelines, this CME-article provides a comprehensive review of the disease.
E, Gallmeier, T M, Gress
openaire   +3 more sources

A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. [PDF]

, 2018
BACKGROUND: Variation in an individual\u27s genetic status can impact the development of pancreatic ductal adenocarcinoma; however, the majority of familial pancreatic cancers (FPC) cannot yet be attributed to a specific inherited mutation.
Brody, Jonathan, Cozzitorto, Joseph A., Goetz, Austin, Lavu, Harish, Muller, Alexander J., Nevler, Avinoam, Prendergast, George C., Winter, Jordan M., Yeo, Charles, Yeo, Theresa P.   +9 more
core   +2 more sources

Deciphering the Crosstalk Between Myeloid-Derived Suppressor Cells and Regulatory T Cells in Pancreatic Ductal Adenocarcinoma

Frontiers in Immunology, 2020
Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with rising incidence and a remarkable resistance to current therapies. The reasons for this therapeutic failure include the tumor's extensive infiltration by immunosuppressive cells such as ...
C. Siret, Aurélie Collignon, F. Silvy, S. Robert, Thierry Cheyrol, P. André, V. Rigot, J. Iovanna, S. A. van de Pavert, D. Lombardo, E. Mas, Anna R Martirosyan   +11 more
semanticscholar   +1 more source

Features of immunophenotype of pancreatic ductal adenocarcinoma

Zaporožskij Medicinskij Žurnal, 2014
Aim. To determine features of immunophenotype of pancreatic ductal adenocarcinoma. Methods and results. At the immunohistochemical research of biopsy and postoperative material of 120 patients with pancreatic ductal adenocarcinoma the expression ...
A. V. Evseyev
doaj   +1 more source

The anti-tumor effect of HDAC inhibition in a human pancreas cancer model is significantly improved by the simultaneous inhibition of cyclooxygenase 2. [PDF]

PLoS ONE, 2013
Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer death worldwide, with no satisfactory treatment to date. In this study, we tested whether the combined inhibition of cyclooxygenase-2 (COX-2) and class I histone deacetylase (HDAC ...
Olivier Peulen, Arnaud Gonzalez, Paul Peixoto, Andrei Turtoi, Denis Mottet, Philippe Delvenne, Vincent Castronovo   +6 more
doaj   +1 more source

Mass-Forming Chronic Pancreatitis: Diagnostic Performance of PET/CT

World Journal of Nuclear Medicine, 2022
Mass-forming chronic pancreatitis and pancreatic ductal adenocarcinoma are most commonly located in the head of pancreas, and there is a marked overlap in clinical features and imaging findings that makes it diagnostically challenging, although prognosis
Ravikanth Reddy
doaj   +1 more source

Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma [PDF]

, 2018
Pancreatic cancer is characterized by nearly universal activating mutations in KRAS. Among other somatic mutations, TP53 is mutated in more than 75% of human pancreatic tumors.
Daylan, Ayse Ece Cali, Del Vecchio, Annachiara, Espinoza, Carlos, Fabo, Tania, Fearon, Eric R., Feng, Ying, Galbán, Stefanie, Halbrook, Christopher J., Karim, Saadia A., Kovalenko, Ilya, Kremer, Daniel M., Kumar-Sinha, Chandan, Lee, Ho-Joon, Ljungman, Mats, Lyssiotis, Costas A., Magnuson, Brian, Morton, Jennifer P., Pasca di Magliano, Marina, Schofield, Heather K., Yan, Wei, Zeller, Jörg   +20 more
core   +1 more source

Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.

JAMA Oncology, 2019
Importance New therapeutic options for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) are needed. This study evaluated dual checkpoint combination therapy in patients with mPDAC.
E. O’Reilly, D. Oh, N. Dhani, D. Renouf, Myung Ah Lee, Weijing Sun, G. Fisher, A. Hezel, Shao-chun Chang, G. Vlahović, O. Takahashi, Y. Yang, D. Fitts, P. Philip   +13 more
semanticscholar   +1 more source